LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

LLY

704.71

+0.12%↑

JNJ

178.66

+0.51%↑

ABBV

208.68

+1.3%↑

UNH

299.83

-1.31%↓

AZN

80.53

+1.23%↑

Search

Regeneron Pharmaceuticals Inc

Closed

SectorHealthcare

591.21 3.55

Overview

Share price change

24h

Current

Min

569.59

Max

596.21

Key metrics

By Trading Economics

Income

583M

1.4B

Sales

647M

3.7B

P/E

Sector Avg

14.471

35.473

EPS

8.22

Dividend yield

0.3

Profit margin

37.86

Employees

15,182

EBITDA

617M

1.7B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+26.29% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.30%

2.38%

Next Earnings

30 paź 2025

Market Stats

By TradingEconomics

Market Cap

515M

61B

Previous open

587.66

Previous close

591.21

News Sentiment

By Acuity

32%

68%

104 / 373 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 sie 2025, 11:33 UTC

Earnings

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

1 sie 2025, 13:16 UTC

Earnings

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 sie 2025, 12:40 UTC

Earnings

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 sie 2025, 10:41 UTC

Earnings

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1 sie 2025, 10:41 UTC

Earnings

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1 sie 2025, 10:40 UTC

Earnings

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1 sie 2025, 10:38 UTC

Earnings

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1 sie 2025, 10:37 UTC

Earnings

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1 sie 2025, 10:35 UTC

Earnings

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1 sie 2025, 10:34 UTC

Earnings

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1 sie 2025, 10:33 UTC

Earnings

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1 sie 2025, 10:32 UTC

Earnings

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1 sie 2025, 10:31 UTC

Earnings

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1 sie 2025, 10:31 UTC

Earnings

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1 sie 2025, 10:30 UTC

Earnings

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1 sie 2025, 10:30 UTC

Earnings

Regeneron Pharma 2Q Rev $3.68B >REGN

1 sie 2025, 10:30 UTC

Earnings

Regeneron Pharma 2Q EPS $12.81 >REGN

1 sie 2025, 10:30 UTC

Earnings

Regeneron Pharma 2Q Net $1.39B >REGN

13 cze 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 cze 2025, 20:45 UTC

Acquisitions, Mergers, Takeovers

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 cze 2025, 20:34 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 cze 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 cze 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 cze 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

5 cze 2025, 01:41 UTC

Acquisitions, Mergers, Takeovers

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30 maj 2025, 08:58 UTC

Hot Stocks

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 maj 2025, 08:56 UTC

Market Talk

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

19 maj 2025, 17:52 UTC

Top News
Acquisitions, Mergers, Takeovers

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19 maj 2025, 16:13 UTC

Acquisitions, Mergers, Takeovers

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

19 maj 2025, 14:42 UTC

Top News
Acquisitions, Mergers, Takeovers

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

Peer Comparison

Price change

Regeneron Pharmaceuticals Inc Forecast

Price Target

By TipRanks

26.29% upside

12 Months Forecast

Average 722.09 USD  26.29%

High 890 USD

Low 543 USD

Based on 25 Wall Street analysts offering 12 month price targets forRegeneron Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

25 ratings

18

Buy

6

Hold

1

Sell

Technical Score

By Trading Central

542.44 / 599.76Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

104 / 373 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.